Treatment of pediatric autoimmune liver disease beyond prednisolone and azathioprine in a cohort of 115 patients.
Korell Marie M, Kramer Miriam M, Poets Alina A, Mutschler Frauke F et al.
Pediatric autoimmune hepatitis (pAIH) is an acute or chronic inflammatory liver disease, caused by a dysregulation of the immune system. Autoimmune sclerosing cholangitis (ASC) additionally affects the bile ducts. Traditional first-line treatment (FLT) consists of prednisolone and azathioprine. If pAIH/ASC remains untreated or biochemical remission (BR) is not achieved, end-stage liver disease develops. We aimed to analyze the 6-months-outcomes of various second- and third-line therapies for pAIH/ASC. This is a retrospective single-center analysis, including all cases of patients with pAIH or ASC between 2000 and 2025. All patients were diagnosed based on published European Society for Paediatric Gastroenterology, Hepatology and Nutrition diagnostic criteria. Of 115 patients with pAIH or ASC, 26 patients required an alternative therapy (altT) other than prednisolone and azathioprine, most of them due to non-BR, including due to non-compliance. The 6-month outcome shows, that tumor necrosis factor (TNF)-alpha inhibitors overall achieved the best results with a BR rate of 40% (n = 2/5). This was closely followed by cyclosporin A (CSA), with a BR rate of 36.4% (n = 4/11), which was the most commonly used drug in our study. Patients with inflammatory bowel disease are significantly more likely to need altT. The overall BR rate 6 months after start of altT is low and decreases with each stage of therapy, the TNF-alpha inhibitors demonstrated the highest BR rate for altT. Non-compliance is a significant problem in general, so it is unclear whether the success of this therapy is solely attributable to the drug's inherent immunomodulatory function or to its controlled administration via intravenous injection. The prospective evaluation of this novel, low-side-effect management option warrants further explorations.